Publications (32) Ana María López González publications

2023

  1. Disease-modifying treatments for patients with multiple sclerosis in Spain

    Farmacia Hospitalaria, Vol. 47, Núm. 4, pp. 155-160

  2. EGFR-mutated advanced lung cancer. Data from a single institution, the Hospital of Leon, in Spain

    Journal of Oncology Pharmacy Practice, Vol. 29, Núm. 4, pp. 854-860

  3. Real world data on the demographic and clinicopathological profile and management of patients with early-stage HER2-positive breast cancer and residual disease treated with adjuvant trastuzumab emtansine (KARMA study)

    Cancer Treatment and Research Communications, Vol. 37

2022

  1. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study

    Cancers, Vol. 14, Núm. 23

  2. Relationship between Aldehyde Dehydrogenase, PD-L1 and Tumor-Infiltrating Lymphocytes with Pathologic Response and Survival in Breast Cancer

    Cancers, Vol. 14, Núm. 18

  3. SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA

    Future Oncology, Vol. 18, Núm. 34, pp. 3791-3800

2020

  1. Fatty acid intake and breast cancer in the Spanish multicase–control study on cancer (MCC-Spain)

    European Journal of Nutrition, Vol. 59, Núm. 3, pp. 1171-1179

2019

  1. Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial

    Breast Cancer Research, Vol. 21, Núm. 1

  2. Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study

    Breast Journal, Vol. 25, Núm. 2, pp. 219-225

2018

  1. Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): An open-label, randomized, three-arm, multicenter, window-of-opportunity study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii64

  2. Experience with eribulin in HR+/HER2- metastatic breast cancer, including a male

    Future Oncology, Vol. 14, Núm. 7s, pp. 5-12

2014

  1. Aldehyde dehydrogenases in early stage lung cancer: nuclear expression

    Clinical and Translational Oncology, Vol. 16, Núm. 10, pp. 931-934

  2. Different exosome cargo from plasma/bronchoalveolar lavage in non-small-cell lung cancer

    Genes Chromosomes and Cancer, Vol. 53, Núm. 9, pp. 713-724

2013

  1. DNA damage and repair in cancer therapy

    Journal of Cancer Science and Therapy, Vol. 5, Núm. 9

  2. False-positive interpretations in respiratory cytopathology

    Clinical Rheumatology, Vol. 32, Núm. SUPPL. 1, pp. 15-17

  3. Mechanisms of resistance to EGFR inhibitors

    Non-Small Cell Lung Cancer: New Research (Nova Science Publishers, Inc.), pp. 155-163

  4. The role of anthracyclines in small cell lung cancer

    Annals of Translational Medicine, Vol. 1, Núm. 1

  5. Use of a tyrosine kinase inhibitor as neoadjuvant therapy for non-small cell lung cancer: A case report

    Respiratory Medicine Case Reports, Vol. 9, Núm. 1, pp. 8-10

2012

  1. Cisplatin: Pharmacology, clinical uses and adverse effects

    Cisplatin: Pharmacology, Clinical Uses and Adverse Effects (Nova Science Publishers, Inc.), pp. 138-148

  2. Skeletal muscle metastasis from NSCLC

    Journal of Thoracic Disease, Vol. 4, Núm. 2, pp. 232-234